Stock price at run: 29.05, Opinion: BUY — Moderate Conviction, Date: Thursday, 2026-10-15 15:08 (EDT).
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to ARQT. [ FAQ on what and how to ask] For non-ARQT questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 3027 Townsgate Road, Suite 300, Westlake Village, CA, United States, 91361
Employees: 354
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
President, CEO & Director
Co-Founder & Director Emeritus
Senior VP & Chief Financial Officer
Executive VP, Chief Legal Officer & Corporate Secretary
Executive VP & Chief Medical Officer
Head of Investor Relations
Vice President of Compliance & Privacy
Head of Corporate Communications
Vice President of Marketing
Senior VP & Chief Human Resources Officer
My Watchlist
